Toxicity Testing Outsourcing Market Size was valued at USD 3.76 Billion in 2023 and is expected to reach USD 8.28 Billion by 2032, growing at a CAGR of 9.2% over the forecast period 2024-2032.
The Toxicity Testing Outsourcing Market report provides key statistical insights and emerging trends, focusing on market growth projections and the increasing demand for outsourced testing services. It includes the incidence and prevalence of toxicity-related cases as it pertain to individual regions and the primary drivers behind the data. It reviews outsourcing trends including cost efficiencies and regulatory advantages, in parallel with a breakdown of toxicity testing spend across government, pharma, and CROs. Additionally, it explores the adoption of alternative testing methods, such as AI-driven models and in-vitro testing, that are replacing traditional approaches. The demand for outsourcing toxicology testing services is also influenced by factors such as rigorous regulatory requirements, the growing emphasis on drug safety, and rising expenditures on research and development. According to the U.S. Food and Drug Administration (FDA), the number of new drug applications (NDAs) and biologics license applications (BLAs) approved in 2024 reached 53, a 15% increase from the previous year. This increase in drug production resulted in a higher need for testing services for toxicity.
Drivers
Stringent regulatory mandates and safety assessment requirements compel companies to outsource toxicity testing to specialized CROs for compliance and efficiency.
Stringent regulatory mandates serve as a key driver for outsourcing toxicity testing in the pharmaceutical and cosmetic industries. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have intensified safety assessment requirements to protect public health. For example, in December 2024, the FDA announced proposed standard testing methods for cosmetic products containing talc to identify the presence of the carcinogen asbestos. The proposed rule would require manufacturers to analyze samples from every batch of talc-containing cosmetics using methods such as polarized light and transmission electron microscopy. Failure to comply may render products adulterated as defined under the Federal Food, Drug, and Cosmetic Act. Drug molecules (biologics and biosimilars) and related products have become more complex in the pharmaceutical industry. Sophisticated analytical testing is necessary to ensure these complex molecules are safe, pure, and effective. Since many pharmaceutical companies do not possess the equipment and expertise to conduct in vivo and even in vitro testing, they often outsource to contract research organizations (CROs) with the appropriate equipment and regulatory know-how. Additionally, this trend is prompted by the desire to comply with strict guidelines from world health authorities, such as the FDA and the European Medicines Agency (EMA). The growing dependence upon external service providers to help navigate complex regulatory environments and comply with changing safety requirements. These trends highlight that strict regulatory requirements play an important role in pushing companies to outsource toxicity testing, and toward that end, Contract Research Organizations (CROs) that specialize in safety assessment.
Restraint:
High costs associated with toxicology testing services can deter companies from outsourcing these essential assessments.
The high pricing of toxicology testing services acts as a key restraint in the market. This is due to the demand for advanced technologies, specialized equipment, and skilled personnel to perform thorough and precise evaluations. As an example, in vitro, toxicology testing methods used in drug discovery are becoming more prevalent because of ethical issues over animal testing, but they need complex assays and high-quality consumables. In toxicology testing, the nature of data management and analysis further drives up costs. In vitro toxicology studies have produced massive datasets that require sophisticated computational methods for their analysis. This can be expensive and a barrier to outsourcing toxicology testing in companies, as maintenance of these tools and handling of the large data needs a lot of monetary investment. Moreover, the absence of consistent protocols and methodologies throughout the industry can result in variability in testing outcomes, requiring companies to invest even more in the reliability and consistency of results. Not only this variability increase operational cost but also elongates the time taken for testing, which finally affects the complete product development pipeline efficiency.
Opportunity:
Expansion into alternative testing methods, such as in vitro assays and computational modeling, offers cost-effective and ethical solutions, aligning with evolving regulatory and industry trends.
The transition to the adverse outcomes pathway (AOP) and other alternative testing methods for toxicity testing, is one of the key opportunities for the global toxicity testing outsourcing market. Ethically, increasingly more scientists justify that animal testing is unnecessary, and politically, the pressure on the substitution of animals for in vitro toxicology tests grows, especially in light of recent technological advancements. Such growth is fueled by the rising use of human-based cell systems like organoids and organ-on-chip systems that have been shown to more accurately mimic human functionality compared to standard animal model systems. And, regulatory changes further reinforce this trend. As a result, the European Union introduced bans on testing cosmetics on animals, and similar policies are being contemplated worldwide. In the United States, policymakers are actively working to identify drug development approaches that lower or replace the need for animal testing. The lack of standardized data and national coordination, as seen in countries like Australia, hampers the full transition to non-animal testing methods. National-level frameworks and dedicated funding to address these issues may help facilitate the global uptake of alternative testing methods.
Challenge:
Ethical concerns and regulations related to animal testing pose significant challenges, prompting the need for alternative testing methodologies.
Outsourcing of toxicity testing is also challenged by ethical concerns and increasing regulations related to the use of animal testing. It is estimated that, in 2022, around 9.3 million had actual experiments performed in the EU, with a further 9.6 million bred and euthanized without experimental use total of 18.9 million animals recorded as used for scientific purposes. Notably, 49% of these procedures were classified as causing moderate to severe suffering. The efficacy of animal testing is increasingly questioned, as 95% of drugs deemed safe in animal trials fail during human clinical stages due to toxicity or inefficacy. Regulations across the world have been introduced to decrease animal testing and this discrepancy. The U.S. Environmental Protection Agency is seeking to reduce mammalian testing by 30% by 2025 and to eliminate it entirely by 2035, for example. Likewise, Spain is pursuing legislation that would give the great apes rights similar to those of humans, outlawing the use of these species in harmful experiments. As a result, companies are now forced to find alternative testing methods like organ-on-chip systems and next-generation in silico models to meet ethical compliance as well as ensure regulatory compliance due to increasingly stringent regulations. Adopting these approaches, along with new technologies, and providing additional staff training and resources is required, which may constitute economic and operational challenges for companies in the toxicity testing outsourcing industry.
By Method
The in vitro segment held the largest share of 56% of the revenue in the global market in 2023. This market share is mainly driven by the rising focus on reducing animal testing, coupled with the increasing acceptance of in vitro methods due to their cost-effectiveness and reliability. The U.S. Environmental Protection Agency (EPA) reported a 30% reduction in animal testing for chemical safety assessments in 2024 compared to 2020, highlighting the shift towards in vitro methods. In addition, in 2025, the U.S. Department of Health and Human Services National Toxicology Program (NTP) reported that 70% of its toxicity testing programs currently use in vitro approaches, compared with 45% in 2020.
The report states that by 2024, 65% of all toxicity data submitted for REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) compliance was sourced from in vitro studies, compared to 52% in 2022, according to the European Chemicals Agency (ECHA). Additionally, an FDA initiative to encourage the use of human-relevant in vitro models also has contributed to a 25% increase in the acceptance of in vitro data for drug safety assessment in 2024 versus 2022. In vitro approaches have also been widely adopted in pharmaceutical and chemical sectors due to the cost efficiency associated with in vitro methods, the NIH estimating that toxicity testing is 40% less expensive with these methods.
By GLP Type
In 2023, the GLP segment held the largest market share. The reason for this dominance is the stringent regulatory requirements enforced by government agencies around the world related to ensuring the quality and integrity of non-clinical laboratory studies. GLP inspections conducted in 2024 were up 15% over 2022, according to the U.S. Food and Drug Administration (FDA), signaling the increasing relevance of GLP compliance in toxicity testing. Additionally, the European Medicines Agency (EMA) announced that 95% of all toxicology data submitted for drug approvals in 2024 were from GLP-certified studies, up from 88% in 2022.
The U.S. Environmental Protection Agency (EPA) doubled down on its GLP requirements, with a 2024 report revealing that 98% of toxicity data used for regulatory decision-making was obtained from GLP-compliant studies, a 5% increase over 2022. In 2025, the National Institute of Environmental Health Sciences (NIEHS) dedicated $50 million to strengthen GLP capabilities in US centers for toxicology research, marking a 25% increase over 2023. This investment demonstrates the government’s commitment to continue setting the highest standards for testing the toxicity of chemicals. In addition, 85% of the countries reported the implementation by the OECD in 2024 of more advanced GLP monitoring programs. This factor is anticipated to contribute to the growth of this segment in the global market.
By end use
The pharmaceutical & biopharmaceutical companies segment led the market and accounted for a revenue share of 62% in 2023. The major typical market share owes to the increasing investment in drug development and the growing pipeline of pharmaceutical products. A 12% rise in the number of investigational new drug (IND) applications was reported by the U.S. Food and Drug Administration (FDA) in 2024 compared with 2023, reflecting the continuing health of the pharmaceutical research enterprise. In 2024, the pharmaceutical industry spent $102 billion on research and development, a 5.8 percent increase from the year prior, according to the National Institutes of Health (NIH). 75% of all marketing authorization applications for new drugs included comprehensive toxicology data sourced from testing services in 2024, compared with 68% in 2023, according to the European Medicines Agency (EMA). This trend underscores the increasing dependence of pharmaceutical companies on specialized toxicity testing providers. Moreover, the number of drugs in clinical development reached a historical high of 6,000 in 2024 an increase of 7% from 2023 according to the Biotechnology Innovation Organization (BIO), driving the need for toxicity testing services even higher. The U.S. Bureau of Labor Statistics estimates that jobs relating to pharmaceutical research and development will grow 17% from 2024 to 2034, highlighting the growth of the sector and its influence on the outsourcing market for toxicity testing.
North America held the largest share in the Toxicity Testing Outsourcing Market, In 2023, North America accounted for a 42% market share, largely owing to its strong pharmaceutical industry and rigorous regulatory landscape. Demand for toxicity testing services is being driven by a 10% increase in new drug approvals in 2024 over 2023 reported by the U.S. Food and Drug Administration (FDA). In 2025, the National Institutes of Health (NIH) spent USD 43.5 billion on biomedical research, which was USD 1.4 billion or 3.5% higher than in 2024 continuing to facilitate regional market growth.
The Asia-Pacific region is expected to grow with the fastest-growing annual growth rate during the forecast period from 2024 to 2032. The rapid growth is attributable to rising investment in pharmaceutical R&D, combined with pro-government initiatives. This could explain the reported 20% new drug clinical trial applications submitted to the China National Medical Products Administration (NMPA) in 2024 compared to 2023. Meanwhile in India, the Department of Biotechnology announced an investment of USD 1.5 billion into biotech research for the period 2025-2030, a 25% increase from its previous five-year plan. Pharmaceutical exports from Japan, rising by 15% in 2024, according to Japan's Ministry of Health, Labour and Welfare, is yet another indication of activity in the industry. Owing to these factors and relatively lower operational costs and an abundance of talent pool, there has been a rapid emergence of toxicity testing outsourcing in the Asia-Pacific region.
Key Service Providers/Manufacturers
Eurofins Scientific (In Vitro Toxicology Services, DiscoveryAI)
SGS SA (Preclinical Safety Testing, In Vitro Toxicology Testing)
Charles River Laboratories (Safety Assessment Services, In Vivo Toxicology Studies)
Thermo Fisher Scientific, Inc. (Cell-Based Assays, ADME-Tox Services)
Intertek Group plc (Regulatory Toxicology Services, Ecotoxicology Testing)
Catalent, Inc. (Preclinical Toxicology Testing, Drug Metabolism Studies)
ICON plc (Nonclinical Safety Assessment, Toxicokinetic Studies)
Medpace (Preclinical Toxicology Services, Safety Pharmacology)
WuXi AppTec (In Vitro Toxicity Testing, In Vivo Toxicology Services)
Labcorp Drug Development (Preclinical Toxicology Services, Genetic Toxicology Testing)
Element Materials Technology (Materials Testing Services, Certification Schemes)
IQVIA (Clinical Trial Execution Services, Data Management Solutions)
Covance Inc. (Safety Assessment Services, Toxicology Testing)
Envigo (Nonclinical Safety Assessment, Reproductive Toxicology)
Toxikon Corporation (Extractables and Leachables Testing, Biocompatibility Testing)
MB Research Laboratories (In Vitro Toxicology Testing, Dermal Irritation Studies)
Charles River Laboratories (Safety Assessment Services, In Vivo Toxicology Studies)
Pharmaron (Preclinical Safety Assessment, Genetic Toxicology)
PRA Health Sciences (Clinical Development Services, Toxicology Testing)
Syneos Health (Early Phase Development, Safety Assessment Services)
Recent developments
In March 2023, Agilent acquired e-MSion, a company that specializes in advanced mass spectrometry technology. e-MSion has been acquired to fill the need as part of Agilent's comprehensive analytical portfolio for biotherapeutic characterization and development.
In March 2024, Pace Analytical boosted its laboratory network by purchasing a facility in Lebanon, New Jersey, from Curia. This acquisition will help to expand Pace's analytical testing service offerings.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 3.76 Billion |
| Market Size by 2032 | USD 8.28 Billion |
| CAGR | CAGR of 9.2% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By GLP Type (GLP, Non GLP) • By Method (In vitro, In vivo) • By End-use (Pharmaceutical And Biopharmaceutical Companies, Academic And Research Institutes, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Eurofins Scientific, SGS SA, Charles River Laboratories, Thermo Fisher Scientific, Inc., Intertek Group plc, Catalent, Inc., ICON plc, Medpace, WuXi AppTec, Labcorp Drug Development, Element Materials Technology, IQVIA, Covance Inc., Envigo, Toxikon Corporation, MB Research Laboratories, Pharmaron, PRA Health Sciences, Syneos Health. |
Ans. The projected market size for the Toxicity Testing Outsourcing Market is USD 8.28 Billion by 2032.
Ans. The CAGR of the Toxicity Testing Outsourcing Market is 9.2% During the forecast period of 2024-2032.
Ans: The North American region dominated the Toxicity Testing Outsourcing Market in 2023.
Ans: Ethical concerns and regulations related to animal testing pose significant challenges, prompting the need for alternative testing methodologies.
Ans: The Pharmaceutical And Biopharmaceutical Companies end-use segment dominated the Toxicity Testing Outsourcing Market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Toxicity-Related Cases (2023)
5.2 Outsourcing Trends in Toxicity Testing (2023)
5.3 Toxicity Testing Expenditure Breakdown (2023)
5.4 Adoption of Alternative Testing Methods (2023)
5.5 Regulatory Compliance and Regional Market Share (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Toxicity Testing Outsourcing Market Segmentation, By GLP Type
7.1 Chapter Overview
7.2 GLP
7.2.1 GLP Market Trends Analysis (2020-2032)
7.2.2 GLP Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Non GLP
7.3.1 Non GLP Market Trends Analysis (2020-2032)
7.3.2 Non GLP Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Toxicity Testing Outsourcing Market Segmentation, By Method
8.1 Chapter Overview
8.2 In vitro
8.2.1 In vitro Market Trends Analysis (2020-2032)
8.2.2 In vitro Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 In vivo
8.3.1 In vivo Market Trends Analysis (2020-2032)
8.3.2 In vivo Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Toxicity Testing Outsourcing Market Segmentation, By End-Use
9.1 Chapter Overview
9.2 Pharmaceutical And Biopharmaceutical Companies
9.2.1 Pharmaceutical And Biopharmaceutical Companies Market Trends Analysis (2020-2032)
9.2.2 Pharmaceutical And Biopharmaceutical Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Academic And Research Institutes
9.3.1 Academic And Research Institutes Market Trends Analysis (2020-2032)
9.3.2 Academic And Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Toxicity Testing Outsourcing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.2.4 North America Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.2.5 North America Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.2.6.2 USA Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.2.6.3 USA Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.2.7.2 Canada Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.2.7.3 Canada Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.2.8.2 Mexico Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.2.8.3 Mexico Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.1.6.3 Poland Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.1.7.3 Romania Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.5 Western Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.6.3 Germany Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.7.2 France Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.7.3 France Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.8.2 UK Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.8.3 UK Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.9.3 Italy Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.10.3 Spain Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.13.3 Austria Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Toxicity Testing Outsourcing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.5 Asia Pacific Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.6.2 China Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.6.3 China Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.7.2 India Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.7.3 India Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.8.2 Japan Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.8.3 Japan Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.9.2 South Korea Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.9.3 South Korea Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.10.3 Vietnam Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.11.2 Singapore Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.11.3 Singapore Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.12.2 Australia Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.12.3 Australia Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Toxicity Testing Outsourcing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.1.4 Middle East Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.1.5 Middle East Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.1.6.3 UAE Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.2.4 Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.2.5 Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Toxicity Testing Outsourcing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.6.4 Latin America Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.6.5 Latin America Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.6.6.2 Brazil Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.6.6.3 Brazil Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.6.7.2 Argentina Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.6.7.3 Argentina Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.6.8.2 Colombia Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.6.8.3 Colombia Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Toxicity Testing Outsourcing Market Estimates and Forecasts, By GLP Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Toxicity Testing Outsourcing Market Estimates and Forecasts, By Method (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Toxicity Testing Outsourcing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
11. Company Profiles
11.1 Eurofins Scientific
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 SGS SA
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Charles River Laboratories
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Thermo Fisher Scientific, Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Intertek Group plc
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Catalent, Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 ICON plc
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Medpace
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 WuXi AppTec
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Labcorp Drug Development
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By GLP Type
GLP
Non GLP
By Method
In vitro
In vivo
By End-use
Pharmaceutical And Biopharmaceutical Companies
Academic And Research Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Type 1 Diabetes Market Size was valued at USD 32.3 billion in 2023 and is expected to reach $63.5 billion by 2032 and grow at a CAGR of 7.82% by 2024-2032.
The Artificial Cornea and Corneal Implant Market was valued at USD 478.73 million in 2023 and is expected to reach USD 910.85 million by 2032, growing at a CAGR of 7.45% from 2024-2032.
The Lab Automation Market size was estimated at USD 7.31 billion in 2023 and is expected to reach USD 13.05 billion by 2032, with a growing CAGR of 6.65% during the forecast period of 2024-2032.
The In Vitro Fertilization (IVF) Market was valued USD 18.82 billion in 2023, anticipated to reach USD 35.83 billion by 2032 with a compound annual growth rate at 7.47% during the forecast period 2024-2032.
The Home Healthcare Software Market valued at USD 12.16 billion in 2023 and is projected to reach USD 38.92 billion by 2032 and grow at a CAGR of 13.8% over the forecast period 2024-2032.
The FemTech Market Size, valued at USD 55.6 billion in 2023, is projected to reach USD 125.35 billion by 2032, growing at a CAGR of 9.47% (2024-2032)
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
